Pasithea Therapeutics Corp. KTTA 深 沪
等待开盘 08-26 09:30:00 美东时间
0.7174
+0.000
+0.04%
华盛通- 最 高0.7253
- 今 开0.7253
- 成交量 6.47万股
- 最 低 0.6901
- 昨 收 0.7171
- 总市值 534.00万
- 52周最高 7.50
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 0.65
- 委 比 -64.98%
- 总股本 744.36万
- 历史最高 170.00
- 量 比 1.07
- 振 幅 4.91%
- 历史最低 0.65
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pasithea Therapeutics Q2 EPS $(0.66) Up From $(3.71) YoY
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.66) per share. This is a 82.21 percent increase over losses of $(3.71) per share from the same period last year.
08-15 05:55
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Pasithea Therapeutics Corp. has completed enrollment and initial dosing of three subjects in Cohort 1 of its Phase 1/1b clinical trial evaluating PAS-004, a next-generation MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) in adults with plexiform neurofibromas. The trial aims to assess safety, tolerability, and preliminary efficacy. PAS-004, administered once daily, may offer improved patient compliance compared to current thera...
07-31 11:01
Pasithea Therapeutics Faces Nasdaq Delisting Notice
An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. O...
06-28 04:41
Kratos Defense & Security Solutions, Inc. Prices Public Offering of Common Stock
<p>Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) has priced an underwritten offering of 12,987,013 shares of its common stock at $38.50 per share, with net proceeds expected to be approximately $483.75 million. The company has granted underwriters a 30-day option to purchase up to an additional 1,948,052 shares. Proceeds will be used to fund investments in national security programs, targeted acquisitions, and general corporate purpose...
06-26 03:14
Pasithea Therapeutics Expands Stock Offering Limit
The latest update is out from Pasithea Therapeutics Corp ( ($KTTA) ). On June 2...
06-21 04:59
Pasithea Adds Drug Expert Dr. James Lee To Guide New Treatment For Crohn's And Other Inflammatory Diseases
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr.
06-11 19:22
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Pasithea Therapeutics Corp. has appointed Dr. James Lee to its scientific advisory board to guide the development of PAS-004 for treating ETS2-driven inflammatory diseases, including IBD, ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis, and ankylosing spondylitis. Dr. Lee, a leading expert in IBD and a clinician scientist at the Francis Crick Institute, published a 2024 study in Nature identifying ETS2 as a key regulator of ma...
06-11 11:02
Pasithea Announces Its PAS-004 Shows Early Activity And Durable Disease Stability In Heavily Pretreated Solid Tumors, Including BRAF-Mutated Melanoma, With Favorable Safety And Pharmacokinetics In Ongoing Phase 1 Dose Escalation Trial
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors ---- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who
06-02 20:14
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
PAS-004, a next-generation macrocyclic MEK inhibitor developed by Pasithea Therapeutics, has shown preliminary clinical activity as a monotherapy in heavily pre-treated, refractory solid tumors. Interim Phase 1 study results presented at the 2025 ASCO Annual Meeting highlight stable disease in 10 out of 16 efficacy evaluable patients, with tumor reductions and prolonged survival. Notably, a patient with stage 4 BRAF-mutated melanoma achieved a 14...
06-02 12:02
Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.
05-16 06:32
